392 related articles for article (PubMed ID: 23433459)
1. The yin and yang of protein kinase C-theta (PKCθ): a novel drug target for selective immunosuppression.
Zhang EY; Kong KF; Altman A
Adv Pharmacol; 2013; 66():267-312. PubMed ID: 23433459
[TBL] [Abstract][Full Text] [Related]
2. An active kinase domain is required for retention of PKCθ at the T cell immunological synapse.
Cartwright NG; Kashyap AK; Schaefer BC
Mol Biol Cell; 2011 Sep; 22(18):3491-7. PubMed ID: 21795397
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C theta (PKCtheta): a key player in T cell life and death.
Hayashi K; Altman A
Pharmacol Res; 2007 Jun; 55(6):537-44. PubMed ID: 17544292
[TBL] [Abstract][Full Text] [Related]
4. NF-kappa B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta.
Coudronniere N; Villalba M; Englund N; Altman A
Proc Natl Acad Sci U S A; 2000 Mar; 97(7):3394-9. PubMed ID: 10716728
[TBL] [Abstract][Full Text] [Related]
5. PKC-theta-mediated signal delivery from the TCR/CD28 surface receptors.
Isakov N; Altman A
Front Immunol; 2012; 3():273. PubMed ID: 22936936
[TBL] [Abstract][Full Text] [Related]
6. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
7. Characterization of protein kinase C theta activation loop autophosphorylation and the kinase domain catalytic mechanism.
Czerwinski R; Aulabaugh A; Greco RM; Olland S; Malakian K; Wolfrom S; Lin L; Kriz R; Stahl M; Huang Y; Liu L; Chaudhary D
Biochemistry; 2005 Jul; 44(28):9563-73. PubMed ID: 16008341
[TBL] [Abstract][Full Text] [Related]
8. PKCtheta: A potential therapeutic target for T-cell-mediated diseases.
Chaudhary D; Kasaian M
Curr Opin Investig Drugs; 2006 May; 7(5):432-7. PubMed ID: 16729719
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C-theta (PKCtheta): it's all about location, location, location.
Altman A; Villalba M
Immunol Rev; 2003 Apr; 192():53-63. PubMed ID: 12670395
[TBL] [Abstract][Full Text] [Related]
10. Novel protein kinase C θ: coronin 1A complex in T lymphocytes.
Siegmund K; Thuille N; Posch N; Fresser F; Baier G
Cell Commun Signal; 2015 Mar; 13():22. PubMed ID: 25889880
[TBL] [Abstract][Full Text] [Related]
11. Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases.
Jimenez JM; Boyall D; Brenchley G; Collier PN; Davis CJ; Fraysse D; Keily SB; Henderson J; Miller A; Pierard F; Settimo L; Twin HC; Bolton CM; Curnock AP; Chiu P; Tanner AJ; Young S
J Med Chem; 2013 Mar; 56(5):1799-810. PubMed ID: 23398373
[TBL] [Abstract][Full Text] [Related]
12. Characterization of TCR-induced phosphorylation of PKCtheta in primary murine lymphocytes.
Thebault S; Ochoa-Garay J
Mol Immunol; 2004 Feb; 40(13):931-42. PubMed ID: 14725789
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C-θ clustering at immunological synapses amplifies effector responses in NK cells.
Merino E; Abeyweera TP; Firth MA; Zawislak CL; Basu R; Liu X; Sun JC; Huse M
J Immunol; 2012 Nov; 189(10):4859-69. PubMed ID: 23077238
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C-theta inhibitors: a novel therapy for inflammatory disorders.
Chand S; Mehta N; Bahia MS; Dixit A; Silakari O
Curr Pharm Des; 2012; 18(30):4725-46. PubMed ID: 22830352
[TBL] [Abstract][Full Text] [Related]
15. Translocation of PKC[theta] in T cells is mediated by a nonconventional, PI3-K- and Vav-dependent pathway, but does not absolutely require phospholipase C.
Villalba M; Bi K; Hu J; Altman Y; Bushway P; Reits E; Neefjes J; Baier G; Abraham RT; Altman A
J Cell Biol; 2002 Apr; 157(2):253-63. PubMed ID: 11956228
[TBL] [Abstract][Full Text] [Related]
16. PKC-θ function at the immunological synapse: prospects for therapeutic targeting.
Zanin-Zhorov A; Dustin ML; Blazar BR
Trends Immunol; 2011 Aug; 32(8):358-63. PubMed ID: 21733754
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C-theta (PKCtheta), a potential drug target for therapeutic intervention with human T cell leukemias.
Villalba M; Altman A
Curr Cancer Drug Targets; 2002 Jun; 2(2):125-37. PubMed ID: 12188914
[TBL] [Abstract][Full Text] [Related]
18. The Novel PKCθ from Benchtop to Clinic.
Hage-Sleiman R; Hamze AB; Reslan L; Kobeissy H; Dbaibo G
J Immunol Res; 2015; 2015():348798. PubMed ID: 26090489
[TBL] [Abstract][Full Text] [Related]
19. Phytocomponent 4-hydroxy-3-methoxycinnamaldehyde ablates T-cell activation by targeting protein kinase C-θ and its downstream pathways.
Akber U; Na BR; Ko YS; Lee HS; Kim HR; Kwon MS; Park ZY; Choi EJ; Han WC; Lee SH; Oh HM; Jun CD
Int Immunopharmacol; 2015 Mar; 25(1):130-40. PubMed ID: 25637768
[TBL] [Abstract][Full Text] [Related]
20. The physical association of protein kinase C theta with a lipid raft-associated inhibitor of kappa B factor kinase (IKK) complex plays a role in the activation of the NF-kappa B cascade by TCR and CD28.
Khoshnan A; Bae D; Tindell CA; Nel AE
J Immunol; 2000 Dec; 165(12):6933-40. PubMed ID: 11120819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
